Skip to main content
AMLX
NASDAQ Life Sciences

Amylyx Q3 Loss Widens to $45.5M as Avexitide Launch Prep Drives Spend; $768.1M Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$30
Mkt Cap
$3.69B
52W Low
$10.83
52W High
$41.14
52W Position info
177% above low
Off High info
27% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

AMLX has more than doubled off its 52-week low of $10.83.

Summary

Amylyx posted a $45.5M Q3 loss as avexitide launch preparation drove R&D and SG&A higher, backed by $768.1M in cash and securities. It also locked in commercial avexitide supply through Bachem and a Polypeptide term sheet with a $30M pre-payment.


Key Events · Earnings and Guidance · AMLX

  • Q3 Loss Widens on Launch Prep

    Net loss was $45.5M ($0.38 per share) versus $34.4M ($0.37) in Q3 2025; nine-month loss reached $130.2M.

  • R&D and SG&A Step Up

    R&D rose 43% to $28.4M on the LUCIDITY/avexitide program; SG&A rose 32% to $21.3M on pre-commercial hiring and marketing.

  • Balance Sheet Funds Launch

    Cash, cash equivalents and marketable securities totaled $768.1M at September 30, 2026, following the August offering's $544.6M net proceeds.

  • Commercial Supply Locked In

    Signed a five-year Bachem manufacturing agreement and a Polypeptide term sheet requiring a $30M non-refundable capacity reservation pre-payment.


Analysis · AMLX · Life Sciences

The widening loss is the price of launch preparation, not distress. Amylyx's quarterly loss grew to $45.5M ($0.38/share) from $34.4M a year ago, as R&D climbed 43% to $28.4M and SG&A rose 32% to $21.3M on staffing and commercial readiness for avexitide ahead of an NDA submission planned by end-2026. The August offering left $768.1M in cash and securities, enough to fund the potential 2027 launch. What's new is the supply chain build-out: a commercial manufacturing agreement with Bachem and a Polypeptide term sheet carrying a $30M non-refundable capacity pre-payment, which locks in long-term avexitide drug supply but adds fixed obligations. On the legal front, the Shih securities class action is now settled ($6.5M, court-approved September 10, 2026), removing one overhang, though derivative suits remain in settlement talks.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AMLX was trading at $30.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $10.83 to $41.14. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AMLX - Latest Insights

AMLX
Sep 08, 2026, 4:54 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $33.88
Real-time Price: $26.20 info
Change: -$7.68 (-23%) info
Market Cap: $3.368B info
AMLX
Aug 20, 2026, 5:28 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $39.71
Real-time Price: $26.20 info
Change: -$13.51 (-34%) info
Market Cap: $3.368B info
AMLX
Aug 20, 2026, 5:27 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $39.71
Real-time Price: $26.20 info
Change: -$13.51 (-34%) info
Market Cap: $3.368B info
AMLX
Aug 19, 2026, 11:06 PM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $38.45
Real-time Price: $26.20 info
Change: -$12.25 (-32%) info
Market Cap: $3.368B info
AMLX
Aug 19, 2026, 4:36 AM EDT
Source: dpa-AFX
Importance Score:
7
Price at Filing: $35.10
Real-time Price: $26.20 info
Change: -$8.90 (-25%) info
Market Cap: $3.368B info